Cyclosporin A for the treatment of graft-versus-host disease in man

Lancet. 1978 Dec;2(8104-5):1327-31. doi: 10.1016/s0140-6736(78)91971-2.

Abstract

Cyclosporin A was given to five patients with acute leukaemia in whom graft-versus-host disease (G.V.H.D.) had developed after bone-marrow transplantation from sibling donors. In all instances the acute erythematous skin reaction of G.V.H.D. resolved within two days, but four of the five patients died. Cyclosporin A in high doses produced anorexia, nausea, and a reversible rise in blood-urea. The four patients who died all had liver damage, but the histological changes varied. Cyclosporin A modifies the acute skin reaction of G.V.H.D. In the management of liver and gut G.V.H.D., and in prophylaxis of G.V.H.D., its role needs to be determined.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Drug Evaluation
  • Female
  • Fungal Proteins / therapeutic use*
  • Graft vs Host Reaction / drug effects*
  • Hepatic Encephalopathy / chemically induced
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Injections, Intramuscular
  • Leukemia, Monocytic, Acute / therapy
  • Leukemia, Myeloid, Acute / therapy
  • Liver Function Tests
  • Male
  • Peptides / administration & dosage
  • Peptides, Cyclic / therapeutic use*
  • Postoperative Complications / drug therapy*
  • Transplantation, Isogeneic

Substances

  • Fungal Proteins
  • Immunosuppressive Agents
  • Peptides
  • Peptides, Cyclic